GLP-1 for diabetes vs weight loss is one of the most confusing questions in medicine right now, and the reason is simple: the drugs are identical. Ozempic and Wegovy are both semaglutide. Mounjaro and Zepbound are both tirzepatide. Same molecule, same manufacturer, different box.
What changes is the label, the top dose, and — the part that hits your bank account — how insurance treats the prescription. Cash prices for these four brands span $199 to $1,999 a month across published telehealth pricing pages. Here is what actually separates the diabetes version from the weight-loss version.
GLP-1 for Diabetes vs Weight Loss: The 60-Second Version
Two molecules. Four brands. Two indications.
| Brand | Molecule | FDA-approved for | Weekly dose range | Cash price cited |
|---|---|---|---|---|
| Ozempic | Semaglutide | Type 2 diabetes | 0.25 mg to 2 mg | $900-$1,100/mo (Ro) |
| Wegovy | Semaglutide | Chronic weight management | 0.25 mg to 2.4 mg | From $199/mo (Ro, Hers) |
| Mounjaro | Tirzepatide | Type 2 diabetes | 2.5 mg to 15 mg | $1,899/mo retail (Hers) |
| Zepbound | Tirzepatide | Chronic weight management | 2.5 mg to 15 mg | From $299/mo (Ro, Hers) |
Read that price column twice. Hers lists retail Mounjaro at $1,899 a month while listing Zepbound — the same tirzepatide — from $299 a month; our Mounjaro cost without insurance breakdown walks through every cheaper route. That is a six-fold spread on one molecule, driven entirely by which box it ships in and which discount channel it moves through.
Cleveland Clinic describes GLP-1 receptor agonists as drugs that mimic a gut hormone to slow stomach emptying, blunt appetite, and prompt insulin release when blood sugar climbs. Those three effects do not know which label they were prescribed under. Your insurer does.
Ozempic vs Wegovy: Same Semaglutide, Different Ceiling
Ozempic is FDA-approved for type 2 diabetes — improving blood sugar alongside diet and exercise, plus reducing cardiovascular risk in adults with type 2 diabetes and known heart disease. Its dose ladder tops out at 2 mg weekly.
Wegovy is the weight-management version, approved in June 2021 as the first new chronic weight-management drug since 2014, per the FDA’s announcement. Its label runs one rung higher: 0.25, 0.5, 1, 1.7, then 2.4 mg weekly, with each step lasting four weeks before the next.
So the entire clinical difference between the two products is 0.4 mg and a maintenance schedule. Everything else — the ingredient, the once-weekly shot, the side-effect profile — is shared.
That gap is why prescribing Ozempic for weight loss is called off-label. It is legal and common, but the weight-loss approval belongs to Wegovy. Ro still lists off-label Ozempic on its menu at $900 to $1,100 a month cash, picked up at a retail pharmacy, versus a Wegovy pen starting at $199. If you want the full breakdown, read our page on Ozempic cost without insurance.
Mounjaro vs Zepbound: Same Doses, Different Paperwork
Tirzepatide is the odder pair, because here the doses do not diverge at all.
Both Mounjaro (approved for type 2 diabetes) and Zepbound (approved in November 2023 for chronic weight management, per the FDA) start at 2.5 mg weekly and climb in 2.5 mg steps to a maximum of 15 mg. Same molecule, same ladder, same ceiling.
Tirzepatide is also mechanically different from semaglutide: it activates two hormone receptors, GIP and GLP-1, not one. That dual action applies identically whether the pen says Mounjaro or Zepbound.
So what separates them? Paperwork and price. The indication on the carton determines which prior-authorization form your prescriber fills out, which formulary tier applies, and whether a telehealth platform will touch it. Hers illustrates the split perfectly: it sells Zepbound formats from $299 a month but lists retail Mounjaro at $1,899 a month — a difference of roughly $1,600 per month for chemically equivalent medicine.
Who Qualifies: A1C Rules vs BMI Rules
The eligibility gates look nothing alike.
For the diabetes indication, the question is metabolic: do you have a confirmed type 2 diabetes diagnosis, what is your A1C, and what are you already taking? Adding a GLP-1 on top of insulin or a sulfonylurea raises hypoglycemia risk, so those doses often need adjusting at the same visit.
For the weight-management indication, the gate is anthropometric: a BMI of 30 or higher, or 27 or higher with at least one weight-related condition such as high blood pressure, high cholesterol, or type 2 diabetes itself. That last item is the overlap zone — plenty of people qualify under both doors.
NIDDK frames prescription weight medications as tools used alongside reduced calories and increased activity, not instead of them. That guidance holds under either indication, and it is the part most marketing pages skip.
One more gate worth knowing: platform rules. Ro requires that you have seen a healthcare provider within the last 3 years to use its service, and Noom’s compounded GLP-1 plans are unavailable in Alabama, Louisiana, and Mississippi.
GLP-1 for Diabetes vs Weight Loss: Why Insurance Treats Them Differently
This is where the two paths really split.
Blood-sugar control sits inside standard medical coverage. Weight management is frequently carved out as its own excluded benefit — which is exactly why a multi-billion-dollar cash-pay telehealth industry grew around the weight-loss indication and not the diabetes one.
The programs themselves show the pattern. Ro offers a free insurance checker plus a concierge that files prior authorizations, a process it says runs 2 to 3 weeks; with coverage, your medication cost may drop to a copay. Noom sells a branded-medication telehealth plan at $39 the first month, then $99 a month billed quarterly, and the drug is billed separately through your insurance or cash — Noom states insurance does not cover the Noom program itself.
Then there is the other camp. Hers does not accept insurance at all, charging $39 the first month, then $149 a month for membership plus medication, with a cheapest all-in combination around $303 a month per third-party pricing reports. bmiMD and MEDVi are cash-pay only as well.
The lesson for anyone comparing quotes: an advertised $99 a month is a cash number, and a $25 copay is an insurance number. They are not the same currency, and only one of them depends on your plan approving the indication.
What the Trials Actually Measured
Weight-loss numbers get quoted constantly without their fine print. Here it is.
The STEP 1 trial, published in the New England Journal of Medicine, tested weekly semaglutide 2.4 mg in adults with overweight or obesity without type 2 diabetes. Average result: 14.9% of body weight over 68 weeks, versus 2.4% on placebo.
The SURMOUNT-1 trial tested tirzepatide in a similar non-diabetic population and reported up to 20.9% at 72 weeks on the highest dose.
Two things follow. First, these are separate trials with different drugs, doses, and timeframes — not a head-to-head. Second, and more relevant here: neither trial enrolled people with type 2 diabetes, so those percentages are not the expected outcome for someone taking a GLP-1 primarily for blood sugar. Diabetes populations were studied in their own trials, and averages describe groups, not individuals.
Why Telehealth GLP-1 Programs Are Weight-Loss Clinics, Not Diabetes Clinics
Scroll any online GLP-1 program and you will notice something: almost none of them advertise diabetes care. There are three structural reasons.
Reason 1 — the business model follows the coverage gap. Diabetes patients usually already have a prescriber and a covered pathway. People seeking weight loss often have neither, so that is where the cash market formed.
Reason 2 — asynchronous care cannot manage diabetes. Hers reviews intake by messaging, typically within 24 hours, with no video visit and no lab work required in most states. MEDVi routes prescriptions through independent clinicians via a partner network with most reviews inside 24 hours. That model is workable for a BMI-based prescription. It is not built for A1C monitoring, glucose logs, or retuning an insulin regimen.
Reason 3 — the cheap tier is compounded, and compounded drugs are not approved for anything. bmiMD sells compounded semaglutide from $99 a month on a 12-month plan billed as $1,188 upfront, and offers no brand-name Wegovy, Zepbound, or Ozempic at all. MEDVi runs compounded semaglutide at $179 the first month, then $299 refills. Both disclose on their own sites that compounded GLP-1s are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality.
That disclosure applies to every indication. The FDA has flagged concerns with unapproved GLP-1 drugs used for weight loss, including dosing errors from multi-dose vials, and in September 2025 it issued a warning letter to Hims and Hers Health dba Hers over compounded semaglutide marketing — one of 55-plus letters sent to compounded GLP-1 sellers that month. Novo Nordisk followed with a patent suit against the company in February 2026.
If you are choosing among platforms on price alone, our ranking of the best GLP-1 programs shows which ones sell FDA-approved brands and which sell compounded product.
If You Have Both Type 2 Diabetes and Obesity
This is the most common real-world scenario, and it comes with a genuine advantage: you may qualify under either label.
That opens two strategies. Under the diabetes indication, coverage is more likely and your endocrinologist or primary care provider is already managing the rest of your regimen. Under the weight-management indication, you get access to the higher semaglutide ceiling of 2.4 mg and to cash pricing that starts around $199 a month for a Wegovy pen.
What you should not do is run both quietly in parallel. Doubling up on two GLP-1 products, or adding a telehealth prescription your diabetes team does not know about, is a real safety problem — especially if you take insulin or a sulfonylurea, where added blood-sugar lowering can tip into hypoglycemia.
Practical checklist: confirm the exact molecule and dose on every label you are handed, tell each prescriber about the other, and ask specifically whether your diabetes medications need adjusting when the GLP-1 starts. A quick way to keep the names straight is our GLP-1 drug list, and if you want the biology behind the appetite effect, start with how Ozempic works.